FDA approves new treatment for certain advanced or metastatic breast cancers - FDA Press Releases

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).

from Food and Drug Administration--Press Releases http://ift.tt/2hzEx3u
via IFTTT